Rapport Therapeutics, Inc. ( (RAPP) ) has shared an announcement.
On March 3, 2025, Rapport Therapeutics announced the appointment of Jeffrey Sevigny as Chief Medical Officer and provided updates on its Phase 2a trials for RAP-219 in refractory focal epilepsy and bipolar mania. The company expects to report topline results for the epilepsy trial in the third quarter of 2025 and plans to initiate a trial for bipolar mania in the same period, with results anticipated in the first half of 2027. These developments are significant for Rapport’s operational focus and strategic positioning in the neuroscience market.
More about Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. is a company focused on precision neuroscience, developing small molecule medicines for central nervous system disorders. The company is advancing its RAP technology platform and clinical programs, including RAP-219, targeting conditions such as refractory focal epilepsy, bipolar disorder, and peripheral neuropathic pain.
YTD Price Performance: -45.46%
Average Trading Volume: 130,700
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $366.9M
Find detailed analytics on RAPP stock on TipRanks’ Stock Analysis page.